Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects

Familial hypercholesterolemia — the inherited condition that keeps LDL cholesterol dangerously high from birth — was long taught as affecting about 1 in 500 people. This meta-analysis of more than 11 million subjects revises that figure and sharpens the case for finding these patients.

In the general population, FH turns out to be commoner than thought: roughly 1 in 313. But the more useful numbers come from concentrating the search. Among people with ischemic heart disease, FH prevalence is 10-fold higher; among those with premature heart disease, 20-fold; among those with severe hypercholesterolemia (LDL ≥190), 23-fold. In other words, the highest-yield places to look for FH are exactly the clinics already seeing high-risk patients.

That is the practical payoff: rather than screen everyone, screen smartly. A young heart-attack patient or anyone with a very high LDL deserves an FH workup and cascade testing of relatives. The study also notes a sobering gap — 91 percent of countries have no prevalence data at all.

We rate the evidence strong. It is a rigorous, enormous meta-analysis that both updates a long-quoted statistic and points to where targeted screening will catch the most undiagnosed disease.